Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


Purpose:

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using [18F]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer. PURPOSE: This phase I trial is studying how well a PET scan using [18F]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.


Study summary:

OBJECTIVES: - Determine whether [18F]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan. OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive [18F]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours. Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the pancreas - Primary or metastatic disease - At least one site of measurable disease - Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141 PATIENT CHARACTERISTICS: Inclusion criteria: - ECOG performance status 0-2 - WBC ≥ 1,200/mm³ - Creatinine < 2.0 mg/dL - Negative pregnancy test - Fertile patients must agree to use effective contraception - Not pregnant or nursing Exclusion criteria: - Allergy to IV contrast - Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan PRIOR CONCURRENT THERAPY: Inclusion criteria: - More than 4 weeks since prior abdominal surgery Exclusion criteria: - Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits - Aprepitant within 72 hours of [18F]-labeled substance P antagonist receptor quantifier positron emission tomography


NCT ID:

NCT00547612


Primary Contact:

Study Chair
Richard E. Royal, MD, FACS
NCI - Surgery Branch


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20892
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.